



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/12, 215/06, 471/04, 487/06		A1	(11) International Publication Number: WO 99/41252
			(43) International Publication Date: 19 August 1999 (19.08.99)
(21) International Application Number: PCT/US99/02918 (22) International Filing Date: 10 February 1999 (10.02.99) (30) Priority Data: 60/074,411 11 February 1998 (11.02.98) US 9805717.7 17 March 1998 (17.03.98) GB (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): YOUNG, Jonathan, R. [US/US]; 126 East Lincoln Avenue, Rahway, NJ/07065 (US). GOULET, Mark, T. [US/US]; 126 East/Lincoln Avenue, Rahway, NJ 07065 (US). WALSH, Thomas, F. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). FISHER, Michael, H. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE			
<div style="text-align: center;"> </div> <div style="text-align: right;">(I)</div>			
(57) Abstract There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE OF THE INVENTION

ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE

BACKGROUND OF THE INVENTION

5 The gonadotropin-releasing hormone (GnRH), also referred
to as luteinizing hormone-releasing hormone (LHRH), is a decapeptide
that plays a key role in human reproduction. The hormone is released
from the hypothalamus and acts on the pituitary gland to stimulate the
biosynthesis and secretion of luteinizing hormone (LH) and follicle-
10 stimulating hormone (FSH). LH released from the pituitary gland is
primarily responsible for the regulation of gonadal steroid production in
both sexes, whereas FSH regulates spermatogenesis in males and
follicular development in females. GnRH agonists and antagonists have
proven effective in the treatment of certain conditions which require
15 inhibition of LH/FSH release. In particular, GnRH-based therapies
have proven effective in the treatment of endometriosis, uterine fibroids,
polycystic ovarian disease, precocious puberty and several gonadal
steroid-dependent neoplasia, most notably cancers of the prostate, breast
and ovary. GnRH agonists and antagonists have also been utilized in
20 various assisted fertilization techniques and have been investigated as a
potential contraceptive in both men and women. They have also shown
possible utility in the treatment of pituitary gonadotrope adenomas,
sleep disorders such as sleep apnea, irritable bowel syndrome,
premenstrual syndrome, benign prostatic hyperplasia, hirsutism, as an
25 adjunct to growth hormone therapy in growth hormone deficient
children, and in murine models of lupus. The compounds of the
invention may also be used in combination with bisphosphonates
(bisphosphonic acids) and other agents, such as growth hormone
secretagogues, e.g. MK-0677, for the treatment and the prevention
30 of disturbances of calcium, phosphate and bone metabolism, in
particular, for the prevention of bone loss during therapy with the GnRH
antagonist, and in combination with estrogens, progesterones,
antiestrogens, antiprogestins and/or androgens for the prevention or
treatment of bone loss or hypogonadal symptoms such as hot flashes
35 during therapy with the GnRH antagonist.

Additionally, a compound of the present invention may be co-administered with a 5a-reductase 2 inhibitor, such as finasteride or epristeride; a 5a-reductase 1 inhibitor such as 4,7b-dimethyl-4-aza-5a-cholestan-3-one, 3-oxo-4-aza-4,7b-dimethyl-16b-(4-chlorophenoxy)-
5 5a-androstane, and 3-oxo-4-aza-4,7b-dimethyl-16b-(phenoxy)-5a-androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5a-reductase 1 and 5a-reductase 2 such as 3-oxo-4-aza-17b-(2,5-trifluoromethylphenyl-carbamoyl)-5a-androstane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and cyproterone
10 acetate, and alpha-1 blockers such as prazosin, terazosin, doxazosin, tamsulosin, and alfuzosin.

Further, a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth
15 hormone deficient children, which will allow them to continue to gain height before fusion of the epiphyses and cessation of growth at puberty.

Further, a compound of the present invention may be used in combination or co-administered with a compound having luteinizing hormone releasing activity such as a peptide or natural
20 hormone or analog thereof. Such peptide compounds include leuporelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterlin and recirelin.

Additionally, a compound of the present invention may be used as described in U.S. Patent No. 5,824,286 which discloses the
25 administration of peptide GnRH antagonists such as Antide and azaline B to premenopausal women to enhance the readability of mammographic film relative to a mammogram effected in the absence of the administration.

Current GnRH antagonists are GnRH-like decapeptides
30 which are generally administered intravenously or subcutaneously presumably because of negligible oral activity. These have amino acid substitutions usually at positions one, two, three, six and ten.

Non-peptide GnRH antagonists offer the possible advantage of oral administration. Non-peptide GnRH antagonists have
35 been described in European Application 0 219 292 and in De, B. et al.,

J. Med. Chem., 32, 2036-2038 (1989), in WO 95/28405, WO 95/29900 and EP 0679642 all to Takeda Chemical Industries, Ltd.

Substituted indoles known in the art include those described in the following patents and patent applications. US Patent
5 No. 5,030,640 discloses alpha-heterocyclic ethanol aminoalkyl indoles which are potent β -agonists. US Patent No. 4,544,663 discloses indolamine derivatives which are allegedly useful as male anti-fertility agents. WO 90/05721 discloses alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents. French
10 patent 2,181,559 discloses indole derivatives with sedative, neuroleptic, analgesic, hypotensive, antiserotonin and adrenolytic activity. Belgian patent 879381 discloses 3-aminoalkyl-1H-indole-5-thioamide and carboxamide derivatives as cardiovascular agents used to treat hypertension, Raynaud's disease and migraine.

15

SUMMARY OF THE INVENTION

The present invention relates to compounds which are non-peptide antagonists of GnRH which can be used to treat a variety of sex-hormone related conditions in men and women, to methods for their
20 preparation, and to methods and pharmaceutical compositions containing said compounds for use in mammals.

Because of their activity as antagonists of the hormone GnRH, the compounds of the present invention are useful to treat a variety of sex-hormone related conditions in both men and women.
25 These conditions include endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasias such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome and benign prostatic hypertrophy.
30 They are also useful as an adjunct to treatment of growth hormone deficiency and short stature, and for the treatment of systemic lupus erythematosus. Further, the compounds of the invention may be useful in *in vitro* fertilization and as contraceptives. The compounds may also be useful in combination with androgens, estrogens, progesterones,
35 antiestrogens and antiprogestogens for the treatment of endometriosis,

fibroids and in contraception. They may also be useful in combination with testosterone or other androgens or antiprogestogens in men as a contraceptive. The compounds may also be used in combination with an angiotensin-converting enzyme inhibitor such as Enalapril or
5 Captopril, an angiotensin II-receptor antagonist such as Losartan or a renin inhibitor for the treatment of uterine fibroids. Additionally, the compounds of the invention may also be used in combination with bisphosphonates (bisphosphonic acids) and other agents, for the treatment and the prevention of disturbances of calcium, phosphate and
10 bone metabolism, in particular, for the prevention of bone loss during therapy with the GnRH antagonist, and in combination with estrogens, progesterones and/or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with the GnRH antagonist.

15 Additionally, a compound of the present invention may be co-administered with a 5a-reductase 2 inhibitor, such as finasteride or epristeride; a 5a-reductase 1 inhibitor such as 4,7b-dimethyl-4-aza-5a-cholestan-3-one, 3-oxo-4-aza-4,7b-dimethyl-16b-(4-chlorophenoxy)-5a-androstane, and 3-oxo-4-aza-4,7b-dimethyl-16b-(phenoxy)-5a-
20 androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5a-reductase 1 and 5a-reductase 2 such as 3-oxo-4-aza-17b-(2,5-trifluoromethylphenyl-carbamoyl)-5a-androstane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and cyproterone acetate, and alpha-1 blockers such as prazosin, terazosin, doxazosin,
25 tamsulosin, and alfuzosin.

Further, a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth hormone deficient children, which will allow them to continue to gain
30 height before fusion of the epiphyses and cessation of growth at puberty.


Further, a compound of the present invention may be used in combination or co-administered with a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof. Such peptide compounds include leuporelin,

gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterlin and recirelin.

Additionally, a compound of the present invention may be used as described in U.S. Patent No. 5,824,286 which discloses the administration of peptide GnRH antagonists such as Antide and azaline B to premenopausal women to enhance the readability of mammographic film relative to a mammogram effected in the absence of the administration.

10 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds of the general formula




15

wherein

A is

20

C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C6 alkenyl, substituted C3-C6 alkenyl, C3-C6 alkynyl, substituted C3-C6 alkynyl, C1-C6 alkoxy, or C0-C5 alkyl-S(O)_n-C0-C5 alkyl, C0-C5 alkyl-O-C0-C5 alkyl, C0-C5 alkyl-NR₁₈-C0-C5 alkyl where R₁₈ and the C0-C5 alkyl can be joined to form a ring,

























25


or a single bond;

R_0 is hydrogen, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, wherein the substituents are as defined below; aryl, substituted aryl, aralkyl or substituted aralkyl, wherein the substituents are as defined for R_3 , R_4 and R_5 ;

5 R_1 is







- R_2 is hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, aralkyl, substituted aralkyl, aryl, substituted aryl, alkyl -OR₁₁,
 5 C₁-C₆(NR₁₁R₁₂), C₁-C₆(CONR₁₁R₁₂) or C(NR₁₁R₁₂)NH;
 R_2 and A taken together form a ring of 5-7 atoms;
 R_3 , R_4 and R_5 are independently hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, CN, nitro, C₁-C₃ perfluoroalkyl, C₁-C₃ perfluoroalkoxy, aryl,

- substituted aryl, aralkyl, substituted aralkyl, $R_{11}O(CH_2)_p$ -, $R_{11}C(O)O(CH_2)_p$ -, $R_{11}OC(O)(CH_2)_p$ -, $-(CH_2)_pS(O)_nR_{17}$, $-(CH_2)_pC(O)NR_{11}R_{12}$ or halogen; wherein R_{17} is hydrogen, C1-C6 alkyl, C1-C3 perfluoroalkyl, aryl or substituted aryl;
- 5 R_3 and R_4 taken together form a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing 1-3 heteroatoms selected from N, O and S;
- R_6 is hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, aryl, substituted aryl, C1-C3 perfluoroalkyl, CN, NO₂, halogen, $R_{11}O(CH_2)_p$ -, $NR_{12}C(O)R_{11}$, $NR_{12}C(O)NR_{11}R_{12}$ or SO_nR_{11} ;
- 10 R_7 is hydrogen, C1-C6 alkyl, or substituted C1-C6 alkyl, unless X is hydrogen or halogen, then R_7 is absent;
- R_8 is hydrogen, $C(O)OR_9$, $C(O)NR_{11}R_{12}$, $NR_{11}R_{12}$, $C(O)R_{11}$, $NR_{12}C(O)R_{11}$, $NR_{12}C(O)NR_{11}R_{12}$, $NR_{12}S(O)_2R_{11}$, $NR_{12}S(O)_2NR_{11}R_{12}$, $OC(O)R_{11}$, $OC(O)NR_{11}R_{12}$, OR_{11} , SO_nR_{11} , $S(O)_nNR_{11}R_{12}$, C1-C6 alkyl or substituted C1-C6 alkyl, unless X is hydrogen or halogen, then R_8 is absent; or
- 15 R_7 and R_8 taken together form a carbocyclic ring of 3-7 atoms;
- R_9 and R_{9a} are independently hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl; aryl or substituted aryl, aralkyl or substituted aralkyl
- 20 when m is not equal to; or
- R_9 and R_{9a} taken together form a carbocyclic ring of 3-7 atoms or $\overset{O}{\parallel}$ when m is not equal to 0;
- R_9 and A taken together form a heterocyclic ring containing 3-7 carbon
- 25 atoms and one or more heteroatoms when $m \neq 0$; or
- R_{10} and R_{10a} are independently hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl; or
- R_{10} and R_{10a} taken together form a carbocyclic ring of 3-7 atoms or $\overset{O}{\parallel}$;
- 30 R_9 and R_{10} taken together form a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing one or more heteroatoms when m is not equal to 0; or

- R₉ and R₂ taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms when m is not equal to 0; or
- R₁₀ and R₂ taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;
- 5 R₁₀ and A taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms; or
- R₁₁ and R₁₂ are independently hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, a carbocyclic ring of 3-7 atoms or a substituted carbocyclic ring containing 3-7 atoms;
- 10 R₁₁ and R₁₂ taken together can form an optionally substituted ring of 3-7 atoms;
- R₁₃ is hydrogen, OH, NR₇R₈, NR₁₁SO₂(C₁-C₆ alkyl),
- 15 NR₁₁SO₂(substituted C₁-C₆ alkyl), NR₁₁SO₂(aryl), NR₁₁SO₂(substituted aryl), NR₁₁SO₂(C₁-C₃ perfluoroalkyl); SO₂NR₁₁(C₁-C₆ alkyl), SO₂NR₁₁(substituted C₁-C₆ alkyl), SO₂NR₁₁(aryl), SO₂NR₁₁(substituted aryl), SO₂NR₁₁(C₁-C₃ perfluoroalkyl); SO₂NR₁₁(C(O)C₁-C₆ alkyl); SO₂NR₁₁(C(O)-substituted C₁-C₆ alkyl); SO₂NR₁₁(C(O)-aryl);
- 20 SO₂NR₁₁(C(O)-substituted aryl); S(O)_n(C₁-C₆ alkyl); S(O)_n(substituted C₁-C₆ alkyl), S(O)_n(aryl), S(O)_n(substituted aryl), C₁-C₃ perfluoroalkyl, C₁-C₃ perfluoroalkoxy, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, COOH, halogen, NO₂ or CN;
- 25 R₁₄ and R₁₅ are independently hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, CN, nitro, C₁-C₃ perfluoroalkyl, C₁-C₃ perfluoroalkoxy, aryl, substituted aryl, aralkyl, substituted aralkyl, R₁₁O(CH₂)_p-, R₁₁C(O)O(CH₂)_p-, R₁₁OC(O)(CH₂)_p-, -(CH₂)_pS(O)_nR₁₇,
- 30 -(CH₂)_pC(O)NR₁₁R₁₂ or halogen; wherein R₁₇ is hydrogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, aryl or substituted aryl;
- R₁₆ is hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, or N(R₁₁R₁₂);

- R₁₈ is hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C(O)OR₉, C(O)NR₁₁R₁₂, C(O)R₁₁, S(O)_nR₁₁;
- R₁₉ is either the definition of R₁₃ or R₁₄;
- X is hydrogen, halogen, N, O, S(O)_n, C(O), (CR₁₁R₁₂)_p; C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl; when X is hydrogen or halogen, R₇ and R₈ are absent; when X is O, S(O)_n, C(O), or CR₁₁R₁₂ only R₇ or R₈ is possible;
- Z is O, S, or NR₁₁;
- m is 0-3;
- n is 0-2;
- p is 0-4; and
- the alkyl, alkenyl and alkynyl substituents are selected from C₁-C₆ alkyl, C₃-C₇ cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, hydroxy, oxo, cyano, C₁-C₆ alkoxy, fluoro, C(O)OR₁₁, aryl C₁-C₃ alkoxy, substituted aryl C₁-C₃ alkoxy, and the aryl substituents are as defined for R₃, R₄ and R₅;
- or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.

Unless otherwise stated or indicated, the following definitions shall apply throughout the specification and claims.

- When any variable (e.g., aryl, heterocycle, R₁, etc.) occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

- The term "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, e.g., methyl (Me), ethyl (Et), propyl, butyl, pentyl, hexyl, heptyl, octyl, nonanyl, decyl, undecyl, dodecyl, and the isomers thereof such as isopropyl (i-Pr), isobutyl (i-Bu), sec-butyl (s-Bu), tert-butyl (t-Bu), isopentane, isohexane, etc.

The term "aryl" includes phenyl and naphthyl. Preferably, aryl is phenyl.

The term "halogen" or "halo" is intended to include fluorine, chlorine, bromine and iodine.

5 The term "heterocycle" or "heterocyclic ring" is defined by all non-aromatic, heterocyclic rings of 3-7 atoms containing 1-3 heteroatoms selected from N, O, and S, such as oxirane, oxetane, tetrahydrofuran, tetrahydropyran, pyrrolidine, piperidine, tetrahydropyridine, tetrahydropyrimidine, tetrahydrothiophene,
10 tetrahydrothiopyran, morpholine, hydantoin, valerolactam, pyrrolidinone, and the like.

 The term "heteroaryl" refers to a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S
15 or N, in which a carbon or nitrogen atom is the point of attachment. The heteroaryl group is optionally substituted with up to three groups.

 Heteroaryl includes aromatic and partially aromatic groups which contain one or more heteroatoms. Examples of this are indole,
20 thiophene, purine, imidazopyridine, pyridine, oxazole, thiazole, oxazine, pyrazole, tetrazole, imidazole, benzimidazole, pyridine, pyrimidine, pyrazine and triazine.

 As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the
25 specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

 In addition, it is well known to those skilled in the art that many of the foregoing heterocyclic groups can exist in more than one
30 tautomeric form. It is intended that all such tautomers be included within the ambit of this invention.

 The optical isomeric forms, that is mixtures of enantiomers, e.g., racemates, or diastereomers as well as individual enantiomers or diastereomers of the instant compound are included.
35 These individual enantiomers are commonly designated according to

the optical rotation they effect by the symbols (+) and (-), (L) and (D), (1) and (d) or combinations thereof. These isomers may also be designated according to their absolute spatial configuration by (S) and (R), which stands for sinister and rectus, respectively.

5 The individual optical isomers may be prepared using conventional resolution procedures, e.g., treatment with an appropriate optically active acid, separating the diastereomers and then recovering the desired isomer. In addition, the individual optical isomers may be prepared by asymmetric synthesis.

10 Additionally, a given chemical formula or name shall encompass pharmaceutically acceptable addition salts thereof and solvates thereof, such as hydrates.

 The compounds of the present invention, while effective themselves, may be formulated and administered in the form of their
15 pharmaceutically acceptable addition salts for purposes of stability, convenience of crystallization, increased solubility and other desirable properties.

 The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The
20 term "pharmaceutically acceptable salt" is intended to include all acceptable salts. Examples of acid salts are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic, methane sulfonic and the like which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or
25 can be used in sustained release or prodrug formulations. Depending on the particular functionality of the compound of the present invention, pharmaceutically acceptable salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such
30 as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenetnylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and


tetramethylammonium hydroxide. These salts may be prepared by standard procedures, e.g. by reacting a free acid with a suitable organic or inorganic base, or alternatively by reacting a free base with a suitable organic or inorganic acid.

5 Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed, e.g. methyl, ethyl, butyl, acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.

10 The compounds of the present invention may have chiral centers other than those centers whose stereochemistry is depicted in formula I, and therefore may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers, with all such isomeric forms being included in the present invention as well as
15 mixtures thereof. Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates are
20 encompassed within the scope of this invention.

 The compounds of the invention are prepared by the following reaction schemes. All substituents are as defined above unless indicated otherwise.


Scheme A



Reaction Scheme A

As shown in reaction Scheme A, treatment of tryptamine (1) with *N*-carboxyphthalimide in an inert organic solvent such as tetrahydrofuran at a temperature of 20-65°C, preferably 65°C, for a period of 12-48 hours gives the corresponding *N*-phthalimidotryptamine derivative (2). The *N*-phthalimidotryptamine (2) could be further modified by treatment with a brominating agent such as pyridinium hydrobromide perbromide, pyrrolidone hydrotribromide, or the like in an inert organic solvent such as tetrahydrofuran, methylene chloride, chloroform, or mixtures thereof at 0-25°C for a period of 30 minutes to 4 hours to provide the 2-bromotryptamine (3). Bromide (3) may be reacted with an arylboronic acid (prepared essentially as described in : Gronowitz, S.; Hornfeldt, A.-B.; Yang, Y.-H. *Chem. Scr.* **1986**, *26*, 311-314.) with palladium (0) catalysis, a weak base such as aqueous sodium carbonate or the like, and a chloride source such as lithium chloride in an inert solvent like toluene, benzene, ethanol, propanol or mixtures thereof at a temperature of 25°-100°C, preferably 80°C, for a period of 1-6 hours to give the 2-aryltryptamine derivative (4). Finally, the phthalimido group may be removed by treatment of (4) with aqueous hydrazine in an inert solvent such as methanol or ethanol at a temperature of 0°-25°C for a period of 4-24 hours to give tryptamine (5).

Scheme B




Reaction Scheme B

5

As shown in reaction Scheme B, the 2-aryltryptamine may be condensed with a carboxylic acid of type (6) using the coupling reagent 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), 1,3-dicyclohexylcarbodiimide (DCC) or the like with or without 1-hydroxybenzotriazole (HOBt) and a tertiary amine base such as N-methylmorpholine (NMM), triethylamine or the like in an inert organic solvent such as methylene chloride, chloroform, dimethylformamide, or mixtures thereof at or near room temperature for a period of 3-24 hours to provide the corresponding amide derivative (7). Alternatively, 2-aryltryptamine (5) can be treated with an active ester or acid chloride of type (8) in an inert organic solvent such as methylene chloride, chloroform, tetrahydrofuran, diethyl ether, or the like and a tertiary amine base such as triethylamine, diisopropylethylamine, pyridine or the like at a temperature of 0°-25°C for 30 minutes to 4 hours to give (7).

Scheme C




5

Reaction Scheme C

As shown in reaction Scheme C, the amide carbonyl of (7) can be reduced by treatment with borane, lithium aluminum
 10 hydride, or equivalent hydride sources in an inert organic solvent such as tetrahydrofuran, diethyl ether, 1,4-dioxane or the like at 25°-100°C, preferably 65°C, for a period of 1-8 hours to give the corresponding amine compound (9).

Scheme D




5

Reaction Scheme D

As shown in reaction Scheme D, the 2-aryltryptamine (5) can be modified by treatment with an aldehyde or ketone of type (10) in the presence of a weak acid such as trifluoroacetic acid (TFA), acetic acid or the like, with or without a dessicant such as 3Å molecular sieves or magnesium sulfate, and a hydride source such as sodium borohydride or sodium cyanoborohydride, in an inert organic solvent such as methanol, ethanol, isopropanol, tetrahydrofuran, dichloromethane, chloroform, or mixtures thereof at a temperature of 0°-25°C for a period of 1-12 hours to give the corresponding secondary or tertiary amine derivative (11).

Scheme E




5

Reaction Scheme E

As shown in reaction Scheme E, treatment of an arylhydrazine or arylhydrazine hydrochloride (12) with an arylcyclopropylketone of type (13) in a polar organic solvent such as methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol, preferably n-butanol, at a temperature of 70°-120°C for a period of 8-24 hours gives 2-aryltryptamine (5). Alternatively, when an arylhydrazine or arylhydrazine hydrochloride (12) is treated with an arylbutyl ketone of type (14) containing a leaving group (chloride, bromide, iodide, *O*-methansulfonate, *O*-trifluoromethansulfonate, or the like) at the 4-position in a polar solvent such as methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol, or mixtures thereof at room temperature for a period of 30 minutes to 2 hours followed by heating to a temperature of 65°-100°C for 4-24 hours, 2-aryltryptamine (5) is produced.

Scheme F




5

Reaction Scheme F

As shown in reaction Scheme F, iodoanilines of type (15) may be reacted with aryl acetylenes, an appropriate palladium (0) catalyst such as tetrakis(triphenylphosphine)palladium, a copper (I) halide such as cuprous bromide in an inert organic solvent such as triethylamine at a temperature of 50°-88°C for a period of 30 minutes to 5 hours to provide the diacylarylene (16). Acetylene (16) may be further modified by treatment with a palladium (II) catalyst such as palladium (II) chloride or palladium (II) acetate in an inert organic solvent such as acetonitrile at a temperature of 50°- 82°C for a period of 30 minutes to 6 hours to give 2-arylimidazole (17).

Scheme G




5

Reaction Scheme G

As shown in reaction Scheme G, treatment of 2-arylimidazole (17) with oxalyl chloride neat or in an inert organic solvent such as methylene chloride, chloroform, dichloroethane, tetrahydrofuran or the like at a temperature of 25°-65°C for a period of 3-24 hours gives the acylchloride adduct (18). The crude product (18) may be reacted with an amine of type (19) in an inert organic solvent such as diethylether, tetrahydrofuran, methylene chloride, chloroform or the like and an amine base such as triethylamine, diisopropylethylamine or pyridine

at a temperature of 0°C-25°C for a period of 30 minutes to 4 hours to provide the amide derivative (20). Amide (20) may be further modified by treatment with a reducing agent such as borane or lithium aluminum hydride in an inert organic solvent such as tetrahydrofuran at elevated temperatures, preferably reflux, for a period of 1-5 hours to give compound (21).


Scheme H



Reaction Scheme H

As shown in reaction Scheme H, N-benzyl derivatives of type (22a) or N-benzyloxycarbonyl derivatives of type (22b) may be reduced to provide the secondary amine analogs (7) by treatment with hydrogen (1 atm) and an appropriate catalyst such as palladium on carbon, palladium hydroxide on carbon, or the like in an inert organic solvent such as tetrahydrofuran, ethyl acetate, methanol, ethanol, or mixtures thereof to which has been added a weak acid such as 30% aqueous acetic acid for a period of 10 minutes to 3 hours or until the aryl group has been removed to give the secondary amine.

Scheme I




5

Reaction Scheme I

As shown in reaction Scheme I, treatment of a nitroindole of type (24) with hydrogen (1 atm) and an appropriate catalyst such as Raney® Nickel in an inert organic solvent such as ethanol, methanol, or the like at room temperature for a period of 2-1/2 hours gives the corresponding aminoindole derivative (25).

Scheme J




15

Reaction Scheme J

As shown in reaction Scheme J, amino- or hydroxyindole (25) may be modified by acylation under a variety of conditions.

- 5 For example, treatment of (25) with an acid chloride, acid anhydride or active ester and an amine base such as triethylamine, diisopropylethylamine, pyridine, or the like in an inert organic solvent such as methylene chloride, chloroform, tetrahydrofuran, or mixtures thereof at 0°C to room temperature for a period of 1 to 12 hours gives the
- 10 corresponding amide or ester derivatives (26). Alternatively (25) may be coupled with a carboxylic acid by one of the many dehydrating agents commonly employed. For instance, treatment of aminoindole (25) with an appropriate carboxylic acid and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), 1,3-dicyclohexylcarbodiimide
- 15 (DCC) or the like with or without 1-hydroxybenzotriazole (HOBt) and a tertiary amine base such as N-methylmorpholine (NMM), triethylamine or the like in an inert organic solvent such as methylene chloride, chloroform, dimethylformamide, or mixtures thereof at or near room temperature for a period of 3-24 hours provides the corresponding amide
- 20 or ester derivative (26).


Scheme K

Reaction Scheme K

As shown in reaction Scheme K, urea or carbamate derivatives of (25) can be prepared by treatment with a carbamoyl chloride of type (27a), or alternatively with an isocyanate reagent of type (27b), and an amine base such as pyridine, triethylamine, diisopropylethylamine, *N*-methylmorpholine or the like in an inert organic solvent such as methylene chloride, chloroform, dimethylformamide, tetrahydrofuran or mixtures thereof at a temperature of 0°-65°C for a period of 1-72 hours to give (28). Compound (25) can also be modified by treatment with a bis(electrophilic) reagent such as phosgene, triphosgene, 1,1'-carbonyldiimidazole, *N,N'*-disuccinimidyl carbonate, or the like with or without the addition of an amine base such as pyridine, triethylamine, diisopropylethylamine, *N*-methylmorpholine in an inert solvent such as methylene chloride, chloroform, or the like at a temperature of -20°-0°C for a period of 20 minutes to 2 hours. After this time, the reaction mixture is treated with an appropriate mono- or disubstituted amine at -20° to 25°C for a period of 1-5 hours to give the urea or carbamate analog (28).

20

Scheme L




Reaction Scheme L

5

As shown in reaction Scheme L, amine (25) can be modified by treatment with an appropriate sulfonyl chloride of type (29) or sulfamyl chloride of type (30) with an amine base such as pyridine, triethylamine, diisopropylethylamine, *N*-methylethanolamine in an inert solvent such as methylene chloride, chloroform, dichloroethane or the like at a temperature of -20°C to 25°C for a period of 20 minutes to 2 hours to give the corresponding *N*-sulfonamide (31) or *N*-sulfamylamide (32) derivatives, respectively.

10


Scheme M



Reaction Scheme M

As shown in reaction Scheme M, the 2-aryltryptamine (33) can be modified by treatment with an epoxide such as (34) in an inert organic solvent such as methanol, ethanol, isopropanol, butanol, tert-butanol, or mixtures thereof at a temperature of 65°-110°C for a period of 8-20 hours to give the corresponding amino-alcohol derivative (35).

Scheme N




Reaction Scheme N

5

As shown in reaction Scheme N, amide derivatives of an acid-containing indole derivative such as (36) can be prepared by treatment with an appropriate amine ($R_{12}R_{11}NH$) and a suitable coupling agent such as benzotriazol-1-yloxy-tris(pyrrolidino) phosphonium hexafluorophosphate (PyBOP), benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), 1,3-dicyclohexylcarbodiimide (DCC) or the like with or without 1-hydroxybenzotriazole (HOBt) and a tertiary amine base such as N-methylmorpholine (NMM), triethylamine or the like in an inert organic solvent such as methylene chloride, chloroform, tetrahydrofuran, dimethylformamide, or mixtures thereof at or near room temperature for a period of 3 hours to 7 days provides the corresponding amide derivative (37).

20

Scheme O



Reaction Scheme O

As shown in reaction Scheme O, the tryptamine **5** can be modified by reaction with an arylsulfonyl chloride such as 2-nitrobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride or 2,4-dinitrobenzenesulfonyl chloride and a hindered amine base such as 2,4,6-collidine, 2,6-lutidine or the like in an inert organic solvent such as methylene chloride to provide the corresponding sulfonamide **38**. Sulfonamides such as **38** can be further modified by reaction with an alcohol of type **39** in the presence of triphenylphosphine and an activating agent such as diethyl azodicarboxylate (DEAD), diisopropyl

azodicarboxylate or the like in an inert organic solvent such as benzene, toluene, tetrahydrofuran or mixtures thereof to give the dialkylsulfonamide adduct. Removal of the sulfonyl group is accomplished by treatment with a nucleophilic amine such
5 as n-propylamine or the like in an inert organic solvent such as methylene chloride to give secondary amines of type 23.

The compounds of the present invention are useful in the treatment of various sex-hormone related conditions in men and women. This utility is manifested in their ability to act as antagonists
10 of the neuropeptide hormone GnRH as demonstrated by activity in the following *in vitro* assays.

Human GnRH receptor binding assay

Crude membranes prepared from CHO cells expressing
15 human GnRH receptors were the sources for GnRH receptor. [¹²⁵I]Buserelin (a peptidyl GnRH analog) was used as the radiolabelled ligand. The binding activity was determined as an IC₅₀ which is the antagonist concentration required to inhibit the specific binding of [¹²⁵I]buserelin to GnRH receptors by 50%.

20

Rat pituitary GnRH receptor binding assay:

Crude plasma membranes prepared from rat pituitary tissues were incubated in a Tris.HCl buffer (50 mM, PH. 7.5) containing bovine serum albumin (.1%), [I-125]D-t-Bu-Ser6-Pro9-ethyl amide-
25 GnRH, and the desired concentration of a test compound. The assay mixtures were incubated at 4°C for 90-120 minutes followed by rapid filtration and repeated washings through a glass fiber filter. The radioactivity of membrane bound radioligands was determined in a gamma-counter. From this data, the IC₅₀ of the radioligand binding
30 to GnRH receptors in the presence of test compound was estimated.

Inhibition of LH release assay:

Active compounds from the GnRH receptor binding assay were further evaluated with an *in vitro* LH release assay to confirm their
35 antagonist activity (blocking GnRH-induced LH release).

1. Sample Preparation

The compounds to be assayed were dissolved and diluted in DMSO. The final concentration of DMSO in the incubation medium was 0.5%.

2. Assay

The Wistar male rats (150-200 grams) were obtained from Charles River Laboratories (Wilmington, MA). Rats were maintained at a constant temperature (25°C) on a 12-hr light, 12-hr dark cycle. Rat chow and water were available *ad libitum*. The animals were sacrificed by decapitation and pituitary glands were aseptically removed and placed in Hank's Balanced Salt Solution (HBSS) in a 50-mL polypropylene centrifuge tube. The collection tube was centrifuged for 5 min at 250 x g, and HBSS was removed by aspiration. Pituitary glands were transferred to a disposable petri plate and minced with a scalpel. The minced tissue was then transferred to a 50-mL disposable centrifuge tube by suspending the tissue fragments in three successive 10-mL aliquots of HBSS containing 0.2% collagenase and 0.2% hyaluronidase. The cell dispersion was carried out in a water bath at 37°C with gentle stirring for 30 min. At the end of the incubation, the cells were aspirated 20 to 30 times with a pipet and the undigested pituitary fragments were allowed to settle for 3 to 5 min. The suspended cells were removed by aspiration, and then subjected to a 1200 x g centrifugation for 5 min. The cells were then resuspended in Culture medium. The undigested pituitary fragments were treated with 30 mL aliquots of the digestion enzymes as above for a total of 3 digestions with the collagenase/hyaluronidase mixture. The resulting cell suspensions were pooled, counted and diluted to a concentration of 3×10^5 cells/ml, and 1.0 ml of this suspension was placed in each well of a 24-well tray (Costar, Cambridge, MA). Cells were maintained in a humidified 5% CO₂-95% air atmosphere at 37°C for 3 to 4 days. The culture medium consisted of DMEM containing 0.37% NaHCO₃, 10% horse serum, 2.5% fetal bovine serum, 1% non-essential amino acids, 1% glutamine, and 0.1% gentamycin. On the day of an experiment, cells were washed three

times 1 1/2 hrs prior to and two more times immediately before the start of the experiment with DMEM containing 0.37% NaHCO₃, 10% horse serum, 2.5% fetal bovine serum, 1% non-essential amino acids(100X), 1% glutamine(100X), 1% Penicillin/Streptomycin(10,000 Units of Penicillin and 10,000 micrograms of Streptomycin per ml), and 25 mM HEPES, pH 7.4. LH release was initiated by adding 1 ml of fresh medium containing test compounds in the presence of 2 nM GnRH to each well in duplicate. Incubation was carried out at 37°C for 3 hr. After incubation, medium was removed and centrifuged at 2,000 x g for 15 min to remove any cellular material. The supernatant fluid was removed and assayed for LH content with a double antibody RIA procedure using materials obtained from Dr. A. F. Parlow (Harbor-UCLA Medical Center, Torrance, CA).

The compounds of formula I are useful in a number of areas affected by GnRH. They may be useful in sex-hormone related conditions, sex-hormone dependent cancers, benign prostatic hypertrophy or myoma of the uterus. Sex-hormone dependent cancers which may benefit from the administration of the compounds of this invention include prostatic cancer, uterine cancer, breast cancer and pituitary gonadotrophe adenomas. Other sex-hormone dependent conditions which may benefit from the administration of the compounds of this invention include endometriosis, polycystic ovarian disease, uterine fibroids and precocious puberty. The compounds may also be used in combination with an angiotensin-converting enzyme inhibitor such as Enalapril or Captopril, an angiotensin II-receptor antagonist such as Losartan or a renin inhibitor for the treatment of uterine fibroids.

The compounds of the invention may also be useful for controlling pregnancy, as a contraceptive in both men and women, for *in vitro* fertilization, in the treatment of premenstrual syndrome, in the treatment of lupus erythematosus, in the treatment of hirsutism, in the treatment of irritable bowel syndrome and for the treatment of sleep disorders such as sleep apnea.

A further use of the compounds of this invention is as

an adjunct to growth hormone therapy in growth hormone deficient children. The compounds may be administered with growth hormone or a compound which increases the endogenous production or release of growth hormone. Certain compounds have been developed which

5 stimulate the release of endogenous growth hormone. Peptides which are known to stimulate the release of endogenous growth hormone include growth hormone releasing hormone, the growth hormone releasing peptides GHRP-6 and GHRP-1 (described in U.S. Patent No. 4,411,890, PCT Patent Pub. No. WO 89/07110, and PCT Patent Pub. No.

10 WO 89/07111) and GHRP-2 (described in PCT Patent Pub. No. WO 93/04081), as well as hexarelin (J. Endocrinol. Invest., 15 (Suppl 4), 45 (1992)). Other compounds which stimulate the release of endogenous growth hormone are disclosed, for example, in the following: U.S. Patent No. 3,239,345; U.S. Patent No. 4,036,979;

15 U.S. Patent No. 4,411,890; U.S. Patent No. 5,206,235; U.S. Patent No. 5,283,241; U.S. Patent No. 5,284,841; U.S. Patent No. 5,310,737; U.S. Patent No. 5,317,017; U.S. Patent No. 5,374,721; U.S. Patent No. 5,430,144; U.S. Patent No. 5,434,261; U.S. Patent No. 5,438,136; EPO Patent Pub. No. 0,144,230; EPO Patent Pub. No. 0,513,974; PCT Patent

20 Pub. No. WO 94/07486; PCT Patent Pub. No. WO 94/08583; PCT Patent Pub. No. WO 94/11012; PCT Patent Pub. No. WO 94/13696; PCT Patent Pub. No. WO 94/19367; PCT Patent Pub. No. WO 95/03289; PCT Patent Pub. No. WO 95/03290; PCT Patent Pub. No. WO 95/09633; PCT Patent Pub. No. WO 95/11029; PCT Patent Pub. No. WO 95/12598; PCT Patent

25 Pub. No. WO 95/13069; PCT Patent Pub. No. WO 95/14666; PCT Patent Pub. No. WO 95/16675; PCT Patent Pub. No. WO 95/16692; PCT Patent Pub. No. WO 95/17422; PCT Patent Pub. No. WO 95/17423; Science, 260, 1640-1643 (June 11, 1993); Ann. Rep. Med. Chem., 28, 177-186 (1993); Bioorg. Med. Chem. Ltrs., 4(22), 2709-2714 (1994); and Proc. Natl. Acad.

30 Sci. USA 92, 7001-7005 (July 1995).

Representative preferred growth hormone secretagogues employed in the present combination include the following:

- 1) N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(1H-indol-3-yl)ethyl]-2-amino-2-methylpropanamide;
- 5 2) N-[1(R)-[(1,2-Dihydro-1-methanecarbonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(1H-indol-3-yl)ethyl]-2-amino-2-methylpropanamide;
- 3) N-[1(R)-[(1,2-Dihydro-1-benzenesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(1H-indol-3-yl)ethyl]-2-amino-2-methylpropanamide;
- 10 4) N-[1(R)-[(3,4-Dihydro-spiro[2H-1-benzopyran-2,4'-piperidin]-1'-yl)carbonyl]-2-(1H-indol-3-yl)ethyl]-2-amino-2-methylpropanamide;
- 15 5) N-[1(R)-[(2-Acetyl-1,2,3,4-tetrahydrospiro[isoquinolin-4,4'-piperidin]-1'-yl)carbonyl]-2-(indol-3-yl)ethyl]-2-amino-2-methylpropanamide;
- 6) N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino-2-methylpropanamide;
- 20 7) N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino-2-methylpropanamide methanesulfonate;
- 25 8) N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(2',6'-difluorophenylmethyloxy)ethyl]-2-amino-2-methylpropanamide;
- 30 9) N-[1(R)-[(1,2-Dihydro-1-methanesulfonyl-5-fluorospiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino-2-methylpropanamide;

- 10) N-[1(S)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl) carbonyl]-2-(phenylmethylthio)ethyl]-2-amino-2-methylpropanamide;
- 5 11) N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-3-phenylpropyl]-2-amino-2-methylpropanamide;
- 10 12) N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-3-cyclohexylpropyl]-2-amino-2-methylpropanamide;
- 15 13) N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-4-phenylbutyl]-2-amino-2-methylpropanamide;
- 14) N-[1(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(5-fluoro-1H-indol-3-yl)ethyl]-2-amino-2-methylpropanamide;
- 20 15) N-[1(R)-[(1,2-Dihydro-1-methanesulfonyl-5-fluorospiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(5-fluoro-1H-indol-3-yl)ethyl]-2-amino-2-methylpropanamide;
- 25 16) N-[1(R)-[(1,2-Dihydro-1-(2-ethoxycarbonyl)methylsulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(1H-indol-3-yl)ethyl]-2-amino-2-methylpropanamide;
- 30 17) N-[1(R)-[(1,2-Dihydro-1,1-dioxospiro[3H-benzothiophene-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino-2-methylpropanamide;

and pharmaceutically acceptable salts thereof.

35 The compounds of the invention may also be used in combination with bisphosphonates (bisphosphonic acids) and other

agents, such as growth hormone secretagogues, e.g. MK-0677, for the treatment and the prevention of disturbances of calcium, phosphate and bone metabolism, in particular, for the prevention of bone loss during therapy with the GnRH antagonist, and in combination with estrogens, progesterones and or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with the GnRH antagonist.

Bisphosphonates (bisphosphonic acids) are known to inhibit bone resorption and are useful for the treatment of bone lithiasis as disclosed in U.S. Patent 4,621,077 to Rosini, et al.

The literature discloses a variety of bisphosphonic acids which are useful in the treatment and prevention of diseases involving bone resorption. Representative examples may be found in the following: U.S. Patent No. 3,251,907; U.S. Patent No. 3,422,137; U.S. Patent No. 3,584,125; U.S. Patent No. 3,940,436; U.S. Patent No. 3,944,599; U.S. Patent No. 3,962,432; U.S. Patent No. 4,054,598; U.S. Patent No. 4,267,108; U.S. Patent No. 4,327,039; U.S. Patent No. 4,407,761; U.S. Patent No. 4,578,376; U.S. Patent No. 4,621,077; U.S. Patent No. 4,624,947; U.S. Patent No. 4,746,654; U.S. Patent No. 4,761,406; U.S. Patent No. 4,922,007; U.S. Patent No. 4,942,157; U.S. Patent No. 5,227,506; U.S. Patent No. 5,270,365; EPO Patent Pub. No. 0,252,504; and J. Org. Chem., 36, 3843 (1971).

The preparation of bisphosphonic acids and halo-bisphosphonic acids is well known in the art. Representative examples may be found in the above mentioned references which disclose the compounds as being useful for the treatment of disturbances of calcium or phosphate metabolism, in particular, as inhibitors of bone resorption.

Preferred bisphosphonates are selected from the group of the following compounds: alendronic acid, etidrononic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, 6-amino-1-hydroxy-hexylidene-bisphosphonic acid, and 1-hydroxy-3(methylpentylamino)-propylidene-bisphosphonic acid; or any pharmaceutically acceptable salt thereof. A particularly preferred bisphosphonate is alendronic acid (alendronate), or a pharmaceutically acceptable salt thereof. An especially preferred

bisphosphonate is alendronate sodium, including alendronate sodium trihydrate. Alendronate sodium has received regulatory approval for marketing in the United States under the trademark FOSAMAX®.

5 Additionally, a compound of the present invention may be co-administered with a 5 α -reductase 2 inhibitor, such as finasteride or epristeride; a 5 α -reductase 1 inhibitor such as 4,7b-dimethyl-4-aza-5 α -cholestan-3-one, 3-oxo-4-aza-4,7b-dimethyl-16b-(4-chlorophenoxy)-5 α -androstane, and 3-oxo-4-aza-4,7b-dimethyl-16b-(phenoxy)-5 α -androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5 α -
10 reductase 1 and 5 α -reductase 2 such as 3-oxo-4-aza-17b-(2,5-trifluoromethylphenyl-carbamoyl)-5 α -androstane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and cyproterone acetate, and alpha-1 blockers such as prazosin, terazosin, doxazosin, tamsulosin, and alfuzosin.

15 Further, a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth hormone deficient children, which will allow them to continue to gain height before fusion of the epiphyses and cessation of growth at puberty.

20 Further, a compound of the present invention may be used in combination or co-administered with a compound having luteinizing hormone releasing activity such as a peptide or natural hormone or analog thereof. Such peptide compounds include leuprorelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin,
25 histrelin, deslorelin, meterlin and recirelin.

For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent
30 to, or subsequent to the administration of the other agent.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
35 Compositions intended for oral use may be prepared according to any

method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide
5 pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium
10 phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the
15 gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

20 Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or
25 olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-
30 cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic
35 alcohols, for example heptadecaethylene-oxycetanol, or condensation

products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy beans, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such

formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension
5 may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among
10 the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition,
15 fatty acids such as oleic acid find use in the preparation of injectables.

Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at
20 the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth
25 washes and gargles.)

The compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be
30 administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Compounds of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of

polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.

The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter, arrest or reverse the progress of the condition. Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug. Preferably, doses of the compound of structural formula I useful in the method of the present invention range from 0.01 to 1000 mg per adult human per day. Most preferably, dosages range from 0.1 to 500 mg/day. For oral administration, the compositions are preferably provided in the form of tablets containing 0.01 to 1000 milligrams of the active ingredient, particularly 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0002 mg/kg to about 50 mg/kg of body weight per day. The range is more particularly from about 0.001 mg/kg to 1 mg/kg of body weight per day.


Advantageously, the active agent of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in dividend doses of two, three or four times daily.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

The following examples illustrate the preparation of some of the compounds of the invention and are not to be construed as limiting the invention disclosed herein.

10

EXAMPLE 1

15 (S)-2-[2-(3,5-dimethylphenyl)-3-[1-methyl-2-(3-pyridol[2,3-b]pyrazin-7-yl-propylamino)-ethyl]-1H-indol-5-yl]-N,N-diethyl-isobutyramide

Step 1A (S)-2-[3-(2-amino-1-methylethyl)-7-bromo-2-(3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropionic acid ethyl ester

20 A mixture of 0.107 g of ethyl 2-(3-bromo-4-hydrazinophenyl)-2-methylpropionate, 0.066 g of (R)-4-chloro-1-(3,5-dimethylphenyl)-3-methylbutan-1-one, and 2.0 mL of *tert*-butanol was stirred at reflux under nitrogen for 16 hours. The cooled solution was concentrated *in vacuo*, and the residue was partitioned between ethyl acetate and a 10% aqueous sodium thiosulfate solution. The organic phase was washed with water and brine, then dried over sodium sulfate, and filtered. The residue from concentration of the filtrate *in vacuo* was purified by flash chromatography on silica gel (chloroform:methanol:ammonium hydroxide, 95:5:1) to give the title compound (53 mg).

Step 1B (S)-2-[3-(2-amino-1-methylethyl)-2-(3,5-dimethylphenyl)-
1H-indol-5-yl]-2-methylpropionic acid ethyl ester

To a solution of (S)-2-[3-(2-amino-1-methylethyl)-7-bromo-2-
5 (3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropionic acid ethyl ester (79
mg in 1 mL methanol) was added 8 mg of 10% palladium on carbon
catalyst. The reaction flask was fitted with a hydrogen balloon,
evacuated and recharged with hydrogen (3 times) and stirred at room
temperature. After 7 hours the reaction was flushed with nitrogen,
10 filtered over diatomaceous earth, concentrated *in vacuo* and purified by
flash chromatography on silica gel (chloroform:methanol, 92:8) to
provide the title compound (68 mg).

Step 1C (S)-2-[3-(2-*tert*-butoxycarbonylamino-1-methylethyl)-2-
15 (3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropionic
acid ethyl ester

To a solution of (S)-2-[3-(2-amino-1-methylethyl)-2-
(3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropionic acid ethyl
ester (2.13 g in 30 mL tetrahydrofuran) at 0°C was added a solution of di-
20 *tert*-butyl dicarbonate (1.9 g in 6 mL tetrahydrofuran) followed by
potassium carbonate (1.2 g in 5 mL water) and the resulting suspension
stirred vigorously at 0°C. After 20 minutes, the reaction was quenched
by the addition of excess saturated aqueous ammonium chloride and the
mixture extracted with ethyl acetate. The organic portion was dried over
25 sodium sulfate and concentrated *in vacuo*. The residue was purified by
flash chromatography on silica gel (hexane:methylene chloride:ethyl
acetate, 7.5:7.5:1) to give the title compound (2.52 g).

Step 1D (S)-2-[3-(2-*tert*-butoxycarbonylamino-1-methylethyl)-2-
30 (3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropionic
acid

To a stirred solution of (S)-2-[3-(2-*tert*-butoxycarbonyl-
amino-1-methylethyl)-2-(3,5-dimethylphenyl)-1H-indol-5-yl]-2-
methylpropionic acid ethyl ester (2.5 g in 80 mL methanol) was added 26
35 mL of 2.0N potassium hydroxide and the mixture heated to 94°C on an

oil bath. After 14 hours the mixture was cooled to 0°C, acidified to pH5 and extracted with ethyl acetate. The organic layer was washed with saturated ammonium chloride, dried over sodium sulfate and concentrated *in vacuo* to give the crude title compound (2.4 g).

5

Step 1E (S)-{2-[5-(1-diethylcarbamoyl-1-methylethyl)-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]-propyl}-carbamic acid *tert*-butyl ester

To a stirred solution of (S)-2-[3-(2-*tert*-butoxycarbonylamino-1-methylethyl)-2-(3,5-dimethylphenyl)-1*H*-indol-5-yl]-2-methylpropionic acid in dry methylene chloride at 0°C is added 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and the reagents allowed to mix for 1 hour. At this time a solution of diethylamine is added and the reaction stirred at room temperature. After 24 hours, the mixture is concentrated *in vacuo* and purified by flash chromatography on silica gel to give the title compound.

Step 1F (S)-2-[3-(2-amino-1-methylethyl)-2-(3,5-dimethylphenyl)-1*H*-indol-5-yl]-*N,N*-diethyl-isobutyramide

To a solution of (S)-{2-[5-(1-diethylcarbamoyl-1-methylethyl)-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]-propyl}-carbamic acid *tert*-butyl ester in methylene chloride at 0°C is added anisole followed by trifluoroacetic acid and the mixture stirred at 0°C. After 2 hours, the mixture is concentrated *in vacuo* and the residual acid removed by azeotrope with toluene. Purification by flash chromatography on silica gel gives the title compound.

Step 1G (S)-2-{2-(3,5-dimethylphenyl)-3-[1-methyl-2-(3-pyrido[2,3-*b*]pyrazin-7-yl-propylamino)-ethyl]-1*H*-indol-5-yl}-*N,N*-diethyl-isobutyramide

To a solution of (S)-2-[3-(2-amino-1-methylethyl)-2-(3,5-dimethylphenyl)-1*H*-indol-5-yl]-*N,N*-diethyl-isobutyramide in dry chloroform at 0 °C is added magnesium sulfate followed by 3-pyrido

[2,3-*b*]pyrazin-7-yl-propionaldehyde and the mixture stirred at low temperature. After 1 hour, a solution of sodium cyanoborohydride is added followed by a solution of acetic acid in methanol and the reaction allowed to warm to room temperature. After 1 hour, the reaction is
5 quenched by the addition of saturated sodium bicarbonate and the mixture extracted with ethyl acetate. The organic portion is washed with saturated aqueous sodium bicarbonate and then dried over sodium sulfate. Purification of the concentrate by flash chromatography on silica gel gives the title compound.

10

PREPARATION OF SYNTHETIC INTERMEDIATES

Ethyl 2-(3-bromo-4-hydrazinophenyl)-2-methylpropionate

15

Step A: Ethyl (+/-)-2-(4-nitrophenyl)propionate

To a solution of 9.76 g (50 mmol) of (+/-)-2-(4-nitrophenyl) propionic acid in 150 mL of absolute ethanol was added 3.0 mL of concentrated sulfuric acid. The resulting solution was stirred at reflux
20 under nitrogen. After 6 hours, the solution was cooled and stirred vigorously as 250 mL of saturated aqueous sodium bicarbonate solution was added gradually. The mixture was then partitioned between 750 mL of ethyl acetate and 500 mL of water. The organic layer was washed with 100 mL of saturated aqueous sodium bicarbonate solution and then with
25 100 mL of saturated aqueous sodium chloride solution. The organic phase was dried over magnesium sulfate, filtered, and concentrated *in vacuo* to give 10.86 g (97%) of an oil; homogeneous by TLC in 9:1 hexane-ethyl acetate. 400 MHz ¹H NMR (CDCl₃) was consistent with the assigned structure.

30

Step B: Ethyl 2-methyl-2-(4-nitrophenyl)propionate

A suspension of 924 mg (23 mmol) of sodium hydride (60% in oil) in 21 mL of dry *N,N*-dimethylformamide was stirred under nitrogen in an ice bath as a solution of 4.68 g (21 mmol) of ethyl (+/-)-2-(4-
35 nitrophenyl)propionate in 20.5 mL of dry *N,N*-dimethylformamide was

added gradually over about 10 minutes. An intense violet color developed during the addition. The mixture was then allowed to warm to room temperature. After about 1 hour, the mixture was again cooled in an ice bath as a solution of 1.44 mL (3.28 g; 23 mmol) of methyl iodide in 5 mL of dry *N,N*-dimethylformamide was added dropwise by syringe over about 10 minutes, while maintaining the internal temperature at 10-15 °C. The mixture was allowed to warm to room temperature, and the color changed to brown. After 1 hour, an additional 187 mL (426 mg, 3 mmol) of iodomethane was added. By the next day, the mixture consisted of a suspension of some grayish solid in a golden liquid. It was stirred vigorously and quenched by gradual addition of 10 mL of 5% aqueous potassium bisulfate solution. The mixture was partitioned between 400 mL of diethyl ether and 400 mL of water. The organic layer was washed with an additional 3 x 400 mL of water and then with 50 mL of saturated aqueous sodium chloride solution. The organic phase was then dried over magnesium sulfate, filtered, and concentrated *in vacuo*. Flash chromatography of the residue on silica gel (elution with 19:1 hexane-ethyl acetate) yielded 4.31 g (87%) of an oil; homogeneous by TLC in 9:1 hexane-ethyl acetate. 400 MHz ¹H NMR (CDCl₃) was consistent with the assigned structure.

Step C: Ethyl 2-(4-aminophenyl)-2-methylpropionate

A mixture of 4.27 g (18 mmol) of ethyl 2-methyl-2-(4-nitrophenyl)propionate, 200 mg of 10% palladium on carbon, and 120 mL of absolute ethanol was shaken with hydrogen (initial hydrogen pressure 47 psig) in a pressure vessel for 2 hours. The catalyst was removed by filtration through Celite under nitrogen, and the filter cake was washed with additional ethanol. Concentration of the filtrate *in vacuo* at up to 50 °C gave 3.74 g (100%) of an oil; homogeneous by TLC in 4:1 hexane-EtOAc. 400 MHz ¹H NMR (CDCl₃) was consistent with the assigned structure. Mass spectrum (ESI): *m/e* = 208 (M + H).

Step D: Ethyl 2-(4-amino-3-bromophenyl)-2-methylpropionate

To a solution of ethyl 2-(4-aminophenyl)-2-methylpropionate (4.74 g in 40 mL dry methylene chloride) at 0°C was added 4.08 g of *N*-

bromosuccinimide and the mixture stirred at low temperature. After 1 hour, the mixture was warmed to room temperature and concentrated *in vacuo*. Purification of the residue by flash chromatography on silica gel (hexane:ethyl acetate, 9:1; then 8:2) gave the title compound, 5.46 g.

5

Step E: Ethyl 2-(3-bromo-4-hydrazinophenyl)-2-methylpropionate

A solution of 0.091 g of ethyl 2-(4-amino-3-bromophenyl)-2-methylpropionate in 0.32 mL of concentrated hydrochloric acid was stirred at -10 to -5°C in an ice-acetone bath as a solution of 0.023 g of sodium nitrite in 0.20 mL of water was added dropwise over about 15 minutes. Stirring was continued at this temperature for an additional 30 minutes. Next, the supernatant was removed by syringe and added dropwise over 10 minutes to a solution of 0.36 g of stannous chloride dihydrate in 0.25 mL of concentrated hydrochloric acid stirred under nitrogen in an ice-acetone bath. The addition was carried out at such a rate that the internal temperature remained at about -5°C. A gummy material separated during the addition. After completion of the addition, stirring was continued at -10 to -5°C for 1 hour. The mixture was then diluted with 60 mL ethyl acetate and washed with sodium carbonate. The organic layer was washed with water and brine then dried over magnesium sulfate. Concentration *in vacuo* gave the crude title compound.

10

15

20

(R)-4-Chloro-1-(3,5-dimethylphenyl)-3-methylbutan-1-one

25

Step AA: (R)-4-hydroxy-3-methylbutyronitrile

To a solution of (S)-3-bromo-2-methyl-propan-1-ol (5.83g in 25 mL dry *N,N*-dimethylformamide) was added 9.33g sodium cyanide and the mixture heated to 80°C on an oil bath. After 4 hours, the mixture was cooled to room temperature, diluted with water and extracted with ethyl acetate. The combined organics were washed with water then brine. Concentration *in vacuo* gave the desired crude product (2.74g).

30

Step BB: (R)-4-methyldihydrofuran-2-one

To a solution of (R)-4-hydroxy-3-methyl-butyronitrile (2.73g in 39 mL ethanol) was added a solution of sodium hydroxide (1.64g in 13 mL water) and the mixture heated to reflux on an oil bath. After 7 hours, the mixture was cooled and made acidic by the addition of 2N hydrochloric acid. The organics were removed in vacuo and the mixture then extracted with 90 mL benzene. The organics were washed with brine and transferred to a reaction flask fitted with a Dean-Stark trap. p-Toluenesulfonic acid (100 mg) was added and the mixture heated to reflux on an oil bath. After 3 hours, the benzene and product (138°C) were collected by distillation under reduced pressure (1.79g).

Step CC: (R)-3-(3,5-dimethylbenzoyl)-4-methyldihydrofuran-2-one

To a solution of (R)-4-methyldihydrofuran-2-one (1.68 g in 40 mL dioxane) were added 5.51g 3,5-dimethylbenzoic acid methyl ester followed by 1.82g sodium hydroxide and the mixture heated to reflux on an oil bath. After 3 hours, the mixture was cooled to room temperature and the pH neutralized by the addition of 0.5N hydrochloric acid. The mixture was then extracted with ethyl acetate and the organic portion washed with brine and dried over sodium sulfate. Purification of the concentrate by flash chromatography on silica gel (hexane:ethyl acetate, 9:1) gave the title compound (2.42g).

Step DD: (R)-4-chloro-1-(3,5-dimethylphenyl)-3-methylbutan-1-one

To a solution of (R)-3-(3,5-dimethylbenzoyl)-4-methyldihydrofuran-2-one (2.42g in 15 mL dioxane) was added 15 mL conc. hydrochloric acid and the mixture heated to reflux on an oil bath. After one hour, the reaction was poured into cold, saturated aqueous sodium bicarbonate. Additional solid sodium bicarbonate was added until all acid was neutralized. This was then extracted with ethyl acetate, washed with brine. Concentration in vacuo provided the title compound (2.12g).

3-Pyrido[2,3-b]pyrazin-7-yl-propionaldehyde

Step AAA: 7-(3,3-diethoxypropyl)-pyrido[2,3-b]pyrazine

To a solution of 9-BBN (10.2 mL of a 0.5M solution in tetrahydrofuran) at 0°C was added dropwise 0.77 mL of acrolein diethyl acetal and the mixture allowed to warm slowly to room temperature. After 15 hours, the mixture was diluted with 12 mL dry tetrahydrofuran followed by the sequential addition of potassium phosphate (1.6 g), palladium(1,1'-bis(diphenylphosphino)ferrocenyl) dichloride (160 mg) and 7-bromo-pyrido[2,3-*b*]pyrazine (924 mg) and then heated to reflux on an oil bath. After 5 hours, the mixture was cooled to 0°C, diluted with 15 mL benzene and the excess reagents quenched by the addition of 2N sodium hydroxide (3.5 mL) and 30% hydrogen peroxide (2.5 mL). The mixture then extracted with ethyl acetate, washed with brine and the concentrate purified by flash chromatography on silica gel (ethyl acetate:hexane, 1:4; then 1:1; then 4:1) to give the title compound (1.2 g).


15

Step BBB: 3-pyrido[2,3-*b*]pyrazin-7-yl-propionaldehyde

















To a solution of 7-(3,3-diethoxypropyl)-pyrido[2,3-*b*]pyrazine (522 mg in 20 mL chloroform) at 0 °C was added 20 mL of 50% aqueous trifluoroacetic acid and the mixture allowed to warm slowly to room temperature. After 30 minutes, the mixture was diluted with methylene chloride and the reaction quenched by the cautious addition of saturated sodium bicarbonate. The organics were concentrated in vacuo and purified by flash chromatography on silica gel (ethyl acetate:hexane, 1:1; then methylene chloride:methanol, 95:5) to give the title compound (0.214 g).





25

Following a procedure similar to that described above, the following compounds were prepared:




30

Example #	X-R ₇ ,R ₈	-(A)-R ₁	
1A			
1B			
1C			
1D			
1E			
1F			
1G			
1H			

1I			
IJ			

WHAT IS CLAIMED IS:


1. A compound of the formula



wherein

A is

C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₃-C₇ cycloalkyl, substituted C₃-C₇ cycloalkyl, C₃-C₆ alkenyl, substituted C₃-C₆ alkenyl, C₃-C₆ alkynyl, substituted C₃-C₆ alkynyl, C₁-C₆ alkoxy, or C₀-C₅ alkyl-S(O)_n-C₀-C₅ alkyl, C₀-C₅ alkyl-O-C₀-C₅ alkyl, C₀-C₅ alkyl-NR₁₈-C₀-C₅ alkyl where R₁₈ and the C₀-C₅ alkyl can be joined to form a ring,







or a single bond;


R₀ is


hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, wherein the substituents are as defined below; aryl, substituted aryl, aralkyl or substituted aralkyl, wherein the substituents are as defined for R₃, R₄ and R₅;

R₁ is










- R₂ is hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, aralkyl, substituted aralkyl, aryl, substituted aryl, alkyl -OR₁₁, C₁-C₆(NR₁₁R₁₂), C₁-C₆(CONR₁₁R₁₂) or C(NR₁₁R₁₂)NH;
- 5 R₂ and A taken together form a ring of 5-7 atoms;
- R₃, R₄ and R₅ are independently hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, CN,

- nitro, C₁-C₃ perfluoroalkyl, C₁-C₃ perfluoroalkoxy, aryl, substituted aryl, aralkyl, substituted aralkyl, R₁₁O(CH₂)_p-, R₁₁C(O)O(CH₂)_p-, R₁₁OC(O)(CH₂)_p-, -(CH₂)_pS(O)_nR₁₇, -(CH₂)_pC(O)NR₁₁R₁₂ or halogen; wherein R₁₇ is hydrogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, aryl or substituted aryl;
- 5 R₃ and R₄ taken together form a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing 1-3 heteroatoms selected from N, O and S;
- 10 R₆ is hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, aryl, substituted aryl, C₁-C₃ perfluoroalkyl, CN, NO₂, halogen, R₁₁O(CH₂)_p-, NR₁₂C(O)R₁₁, NR₁₂C(O)NR₁₁R₁₂ or SO_nR₁₁;
- R₇ is hydrogen, C₁-C₆ alkyl, or substituted C₁-C₆ alkyl, unless X is hydrogen or halogen, then R₇ is absent;
- 15 R₈ is hydrogen, C(O)OR₉, C(O)NR₁₁R₁₂, NR₁₁R₁₂, C(O)R₁₁, NR₁₂C(O)R₁₁, NR₁₂C(O)NR₁₁R₁₂, NR₁₂S(O)₂R₁₁, NR₁₂S(O)₂NR₁₁R₁₂, OC(O)R₁₁, OC(O)NR₁₁R₁₂, OR₁₁, SO_nR₁₁, S(O)_nNR₁₁R₁₂, C₁-C₆ alkyl or substituted C₁-C₆ alkyl, unless X is hydrogen or halogen, then R₈ is absent; or
- R₇ and R₈ taken together form a carbocyclic ring of 3-7 atoms;
- 20 R₉ and R_{9a} are independently hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl; aryl or substituted aryl, aralkyl or substituted aralkyl when m is not equal to 0; or
- R₉ and R_{9a} taken together form a carbocyclic ring of 3-7 atoms or $\overset{\text{O}}{\parallel}$ when m is not equal to 0;
- 25 R₉ and A taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms when m is not equal to 0; or
- R₁₀ and R_{10a} are independently hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, aryl, substituted aryl, aralkyl or substituted
- 30 aralkyl; or
- R₁₀ and R_{10a} taken together form a carbocyclic ring of 3-7 atoms or $\overset{\text{O}}{\parallel}$;

- R₉ and R₁₀ taken together form a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing one or more heteroatoms when m is not equal to 0; or
- R₉ and R₂ taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms when m is not equal to 0; or
- R₁₀ and R₂ taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;
- R₁₀ and A taken together form a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms; or
- R₁₁ and R₁₂ are independently hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, a carbocyclic ring of 3-7 atoms or a substituted carbocyclic ring containing 3-7 atoms;
- R₁₁ and R₁₂ taken together can form an optionally substituted ring of 3-7 atoms;
- R₁₃ is hydrogen, OH, NR₇R₈, NR₁₁SO₂(C₁-C₆ alkyl), NR₁₁SO₂(substituted C₁-C₆ alkyl), NR₁₁SO₂(aryl), NR₁₁SO₂(substituted aryl), NR₁₁SO₂(C₁-C₃ perfluoroalkyl); SO₂NR₁₁(C₁-C₆ alkyl), SO₂NR₁₁(substituted C₁-C₆ alkyl), SO₂NR₁₁(aryl), SO₂NR₁₁(substituted aryl), SO₂NR₁₁(C₁-C₃ perfluoroalkyl); SO₂NR₁₁(C(O)C₁-C₆ alkyl); SO₂NR₁₁(C(O)-substituted C₁-C₆ alkyl); SO₂NR₁₁(C(O)-aryl); SO₂NR₁₁(C(O)-substituted aryl); S(O)_n(C₁-C₆ alkyl); S(O)_n(substituted C₁-C₆ alkyl), S(O)_n(aryl), S(O)_n(substituted aryl), C₁-C₃ perfluoroalkyl, C₁-C₃ perfluoroalkoxy, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, COOH, halogen, NO₂ or CN;
- R₁₄ and R₁₅ are independently hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, CN, nitro, C₁-C₃ perfluoroalkyl, C₁-C₃ perfluoroalkoxy, aryl, substituted aryl, aralkyl, substituted aralkyl, R₁₁O(CH₂)_p-, R₁₁C(O)O(CH₂)_p-, R₁₁OC(O)(CH₂)_p-, -(CH₂)_pS(O)_nR₁₇,


- $-(CH_2)_pC(O)NR_{11}R_{12}$ or halogen; wherein R_{17} is hydrogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, aryl or substituted aryl;
- R₁₆ is hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, or N(R₁₁R₁₂);
- 5 R₁₈ is hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C(O)OR₉, C(O)NR₁₁R₁₂, C(O)R₁₁, S(O)_nR₁₁;
- R₁₉ is either the definition of R₁₃ or R₁₄;
- X is hydrogen, halogen, N, O, S(O)_n, C(O), (CR₁₁R₁₂)_p; C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl; when X is hydrogen or halogen,
- 10 R₇ and R₈ are absent; when X is O, S(O)_n, C(O), or CR₁₁R₁₂ only R₇ or R₈ is possible;
- Z is O, S, or NR₁₁;
- m is 0-3;
- 15 n is 0-2;
- p is 0-4; and
- the alkyl, alkenyl and alkynyl substituents are selected from C₁-C₆ alkyl, C₃-C₇ cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, hydroxy, oxo, cyano, C₁-C₆ alkoxy, fluoro, C(O)OR₁₁, aryl C₁-C₃ alkoxy, substituted aryl C₁-C₃ alkoxy, and the aryl substituents are as defined for R₃, R₄ and R₅;
- 20 or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof.
- 25

2. The compound according to Claim 1 of the formula



wherein A, R₁ and X-R₇,R₈ are as indicated in the table below:

X-R ₇ ,R ₈	-(A)-R ₁



3. A pharmaceutical composition which comprises an effective amount of a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

4. A method for antagonizing gonadotropin-releasing hormone in a subject in need thereof which comprises administering to said subject an effective amount of a compound as defined in Claim 1 to a subject suffering from a gonadotropin-releasing hormone derived disorder.

5. A method according to Claim 4 wherein the gonadotropin-releasing hormone derived disorder is a sex-hormone related condition.

6. A method according to Claim 4 wherein the gonadotropin-releasing hormone derived disorder is a sex hormone dependent cancer, benign prostatic hypertrophy or myoma of the uterus.

7. A method according to Claim 6 wherein the sex hormone dependent cancer is selected from the group consisting of

prostatic cancer, uterine cancer, breast cancer and pituitary gonadotrophe adenomas.

8. A method according to Claim 5 wherein the sex
5 hormone related condition is selected from the group consisting of endometriosis, polycystic ovarian disease, uterine fibroids and precocious puberty.

9. A method for preventing pregnancy in a subject in
10 need thereof which comprises administering an effective amount of a compound as defined in Claim 1.

10. A method for treating lupus erythematosus in a
subject in need thereof which comprises administering to said subject
15 an effective amount of a compound as defined in Claim 1.

11. A method for treating irritable bowel syndrome in a
subject in need thereof which comprises administering to said subject
an effective amount of a compound as defined in Claim 1.
20

12. A method for treating premenstrual syndrome in a
subject in need thereof which comprises administering to said subject
an effective amount of a compound as defined in Claim 1.

13. A method for treating hirsutism in a subject in need
25 thereof which comprises administering to said subject an effective amount of a compound as defined in Claim 1.

14. A method for treating short stature or a growth
30 hormone deficiency in a subject in need thereof which comprises administering to said subject an effective amount of a compound which stimulates the endogenous production or release of growth hormone and an effective amount of a compound as defined in Claim 1.

15. A method for treating sleep disorders such as sleep apnea in a subject in need thereof which comprises administering to said subject an effective amount of a compound as defined in Claim 1.

5 16. The method of Claim 15 wherein the sleep disorder is sleep apnea.

10 17. A mammographic method in which the image on the mammographic film has enhanced readability relative to a mammogram effected in the absence of the method, which comprises administering to a premenopausal woman an effective amount of a compound as defined in Claim 1.

15 18. A pharmaceutical composition which comprises an inert carrier and an effective amount of a compound which stimulates the endogenous production or release of growth hormone in combination with a compound as defined in Claim 1.

20 19. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier therefor.

25 20. A process for making a pharmaceutical composition comprising combining a compound of Claim 1 and a pharmaceutically acceptable carrier.

30 21. Pharmaceutical therapy comprising co-administration of a compound having luteinizing hormone releasing hormone activity with a compound of Claim 1.

22. The therapy of Claim 21 wherein the compound having luteinizing hormone releasing hormone activity is a peptide compound.

23. The therapy of Claim 22 wherein the peptide compound is a natural hormone or an analog thereof.

24. The therapy of Claim 22 wherein the peptide
5 compound is a compound selected from the group consisting of leuprorelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterelin and recirelin.

25. Pharmaceutical combination therapy comprising a
10 compound having luteinizing hormone releasing hormone activity in combination with a compound of Claim 1.

26. The therapy of Claim 25 wherein the compound
15 having luteinizing hormone releasing hormone activity is a peptide compound.


27. The therapy of Claim 26 wherein the peptide compound is a natural hormone or an analog thereof.

20 28. The therapy of Claim 26 wherein the peptide compound is a compound selected from the group consisting of leuprorelin, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterelin and recirelin.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/02918

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :C07D 401/12, 215/06, 471/04, 487/06 US CL :546/17, 18, 121, 122, 176; 544/236 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 546/17, 18, 121, 122, 176; 544/236 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X, P	US 5,849,764 A (GOULET et al.) 15 December 1998, col. 3, lines 20-35.	1-28																		
X, P	US 5,756,507 A (GOULET et al.) 26 May 1998, col. 3, lines 15-30.	1-28																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
B earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family																		
O document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 07 JUNE 1999		Date of mailing of the international search report 29 JUN 1999																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer DOMINIC KEATING Telephone No. (703) 308-1234 JOYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX 																		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/02918

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/02918

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, the invention according to claim 1, formula I, wherein R1 is pyridotriazine or pyridopyrazole.

Group II, the invention according to claim 1, formula I, wherein R1 is pyridopyrazine.

Group III, the invention according to claim 1, formula I, wherein R1 is imidazopyridine.

Group IV, the invention according to claim 1, formula I, wherein R1 is naphthyridine.

Group V, the invention according to claim 1, formula I, wherein R1 is quinoline.

Claims 1-28 will be examined, commensurate with the elected invention.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The common structural feature in the claims is phenyl substituted indole, which is known in the art and therefore cannot be the special technical feature. The R1 groups, such as pyridotriazine and quinoline, are structurally distinct.